Introduction
In the comparison of survival curves of treatment groups, the proportional-hazards regression model (Cox, 1972) is often used to adjust for covariates such as patient age, functional status and disease stage. It is shown that the formula for the sample size required for the comparison of two groups with exponential curves is valid when the proportional-hazards regression model is used to adjust for covariates. A brief tutorial on determining sample size is presented.
The hazard function evaluated at t is the instantaneous probability of death at a time, t, given survival up to that time. A patient's hazard function will depend on the treatment he or she receives as well as on the characteristics of the patient. Sometimes patients have a decreased probability of death after they survive past the first or second year, that is, the hazard function decreases. On the other hand, in long-term studies the hazard function increases as age increases the probability of death.
Suppose that there are two treatments, A and B. The proportional-hazards model specifies that the ratio of the hazard function of a patient given Treatment B to the same patient given Treatment A will be a constant, denoted by A, irrespective of time or the characteristics of the patient. Thus, one parameter specifies the effect of treatment. If survival is improved more by Treatment A than by Treatment B, A will be greater than 1. The assumption of proportional hazards is reasonable whenever the effect of treatment is constant over time or treatment permanently effects the disease process. If treatment has a transitory effect, then tests based on the proportional-hazards model should not be used and the sample-size formula given here is not valid. Tests appropriate to this situation have been given by Fleming et al. (1980) .
Sample-Size Formula
The sample-size formula for a clinical trial can be simplified if it is expressed as the number of deaths required rather than as the number of patients. Suppose that a one-sided test will be performed with a significance level of a and a power of P when the hazard ratio is Ao. Let zl-,and zp be the 1 -a and p percentiles of the normal distribution, respectively, and let PA and PB be the proportion of the patients randomized to Treatments A and B, respectively.
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Covariates; Logrank test; Power; Survival; Two-sample tests. Biometries, June 1983 Assume that treatment effect is tested by an appropriate test based on the partial likelihood (Cox, 1972) . Then the total number of deaths required is given by the following expression which is derived in the Appendix: This is the same formula as that used to calculate sample size when two homogeneous patient groups are compared by using the F test for exponential survival (Bernstein and Lagakos, 1978) , or when the logrank test is used to compare treatments with proportional hazards without covariates (Schoenfeld, 1981) . However, this does not imply that covariate analysis is without benefit (see $3).
The number of patients required for a study is the same whether the randomization is stratified by covariate values or a simple randomization is used. The formula is not valid in a study where covariates are likely to be extremely unbalanced, such as a nonrandomized study.
Determining the Proportion of Patients that Will Die
Clinical trials have an accrual period, a, the period during which patients enter the study, and a follow-up period,f, the period from the end of accrual until the analysis of the data. The follow-up period substantially reduces the number of patients required in a clinical trial because without it, little information would be provided by patients who entered the trial near the end of the accrual period.
In a clinical trial with an accrual period, a, and a follow-up period, f, the proportion of patients that will survive is the average of the survival curve from Time f to Time a +f, provided that patients enter the trial at a constant rate. Thus if one has conducted a previous trial using Treatment B and has an estimate of the survival curve SB(t), one can use Simpson's rule to approximate the proportion of patients that will die on Treatment B:
The proportion that will die on Treatment A can be approximated by d~ = 1 -(1 -d~)'/". Finally, the proportion dying in the trial is given by The number of patients required for the trial is equal to the number of deaths given by (I), divided by d.
This approximation for d~ is slightly conservative in that it underestimates the proportion of deaths on Treatment A. If the covariates divide the patient population into J groups with frequencies UI, Uz, . . . , UJ and survival curves S~l ( t ) , . . . , SBJ(~), then a better approximation would be
However, if A s 2, .1 s SBj(a +f ) and S B~C~) s .9, then the error in the approximate formula is less than .16 d~ .
If the survival is exponential within each group with the same covariates, a more precise calculation is possible. If the median survival of a subgroup on Treatment B is t, the proportion expected to die will be 1 -{exp(-.69f/t)){l -exp(-.69a/t))/(.69a/t). Then d~ will be the average of these values weighted by the proportions of patients in each prognostic subgroup. The median survival on Treatment A in a subgroup will be At, and d~ can be calculated by using the same formula. Sample-Size Formula
Using the Nomograms to Determine Sample Size
The nomograms given by Schoenfeld and Richter (1982) can be used to determine sample size when covariates are to be included in the analysis. To use the nomograms, simply calculate the proportion of the patients predicted to die, as in $2.1. The tick marks on the horizontal scale of the nomogram correspond to the proportions of patients that will die in a clinical trial. The first corresponds to lo%, the second to 20%, and so on. Therefore, mark the percentage that will die on the horizontal scale of the proper nomogram; draw a vertical line from this point to the graph with R = A; then draw a horizontal line from this point of intersection to the vertical scale and read the number of patients required per arm.
The Power Advantages of Adjusting for Covariates
Even though the formula for sample size is the same whether covariates are adjusted for or not, the powers of the two procedures are different. If the two treatment groups follow the proportional-hazards regression model, then, if covariates are ignored, the ratio of the hazard functions of the two groups will be nonproportional. This ratio will be less than A at every value of t > 0 and the power of any test without covariates will be less than that of the test that uses covariates.
As an example, suppose that there is a binary covariate which divides the patient population into two equal groups. Patients in Treatment Group B have a median survival of two years in one group and of six months in the other. Survival is exponential and A = 1.5, so patients in Group A have a median survival of three years in one group and of nine months in the other. The ratio of the hazard functions at the start of the study will be 1.5, however by the second year, the hazard ratio will have dropped to 1.27. In a clinical trial conducted with two years of accrual and two years of follow-up, the logrank test will have an efficiency of 61% when compared to a test that uses the covariate. For the calculation involved, see Schoenfeld (1981) . If the hazard ratio were not constant and if we used the optimal rank test, its efficiency would only be 63%. Thus, the use of covariates can substantially increase power when the proportional-hazards model holds.
Example
The Radiation Therapy Oncology Group is conducting a series of trials on the treatment of primary brain cancer. The first study, completed in 1978, showed an advantage of chemotherapy and radiation therapy over radiation therapy alone. Subsequent studies are testing whether the addition of a radiation sensitizer or the use of neutron radiotherapy improves survival. In this example, it is shown how the data from the first study can be used to plan a new study.
The new study would use chemotherapy and radiation therapy for its standard arm. A Table 1 Prognostic subgroups in primary brain tumors total of 272 patients were treated with this combination in the first study. The most important prognostic factors were age and whether the patients had necrosis in their surgical specimens. Table 1 shows the numbers of patients in three age groups and two necrosis groups. Of the 272 patients, 43% survived past one year, 20% past two years, and 11% past three years. For a study with an accrual period of two years and one year of additional follow-up, the proportion of deaths is computed to be 1 If covariates were ignored in subsequent studies, the efficiency of a logrank test for comparing treatments would only be 67%. Even if the optimal rank test were used, its efficiency would only be 70%. Thus, the use of these covariates substantially reduces the sample size needed to achieve adequate power.
This work was funded by Grants CA-25162and CA-23415of the National Cancer Institute. I wish to express my appreciation to the Radiation Therapy Oncology Group for providing the example.
This allows stratification based on yJ, as long as the proportion randomized to each treatment IS the same in each stratum. Assume that the hazard function for the jth patient is given by where the summation is over the set i = 1,p, and a. = log, A.
To define the score statistic (Rao, 1973, p. 417) , let D be the set of identifiers of those patients who die, let tJ be the death time for the jth patient in D, and let xJ denote the patient's treatment label. Assume the t , are distinct. Let R(tJ) be the set of identifiers of patients being observed at Time tJ -0. For any function g(x, y), define and let $ be EJ with maximum likelihood estimates (assuming ao = 0) replacing the parameters (a,}.
Letting y, be the ith compound of y, we define the elements of the p x 1 vector B by
and we define the elements of the p x p matrix M by
The score statistic can then be expressed as
The term B'M-'B is the effect of the estimation of al, a2, . . . , a, on the variance of xJ -zJ(x).
Assume that a. u ~( n -l ) .
At the start of the trial, the distribution of vecto~s y wilj be_ the _same in the Lwoptreatment groups. Since a" + 0, this will remain true for any time, t, so EJ(xj,) + EJ(x)EJ(y,). Thus B -t 0 and the_ second term in the denominator of S can be ignored. The term B appears in the Taylor expansion of E(x) about a l , a2, . . . , a,, which implies that n -i 2 {ZJ(x)-EJ(x)) Z 0. J E D Thus S can be written as
Define
The numerator of S can be written
The first term is asymptotically normal with mean 0 and variance n 1 1eJ(l -el), where the summation is over D (Cox, 1975; Tsiatis, 1981) . Expanding the second term in a Taylor series about a. = 0, we find that this term approaches a. n-l 1EJ(x){ I -EJ(x)}. However, since a. -t 0, both eJ and EJ(x) approach P I . Thus S is asymptotically normal with unit variance and mean equal to ao(P1 P2)himes the square root of the expected number of deaths on the trial. This yields (1).
